9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingFeatured News
Tag: Pieter Rottiers
Recent Posts
- Please Join Us for the Teal Pumpkin Project 2024!
- Why Aren't Most Rice Krispy Treats Gluten-Free?
- The 2024 Nobel Prize in Chemistry goes to a leading celiac disease researcher
- Cooking Up Health: New Paper Details How Culinary Medicine Can Empower Patients Living with Chronic Diseases
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
9/26/2024
Read more2024 International Celiac Disease Symposium Recap
Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...